ArticleOncotarget2017
Choroidal microvascular proliferation secondary to diabetes mellitus.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Safety and efficacy of AAV8-aflibercept in treating choroidal neovascularization via single-cell RNA sequencing.Molecular therapy. Methods & clinical development · 2025Article
- Advancements and emerging trends in ophthalmic anti-VEGF therapy: a bibliometric analysis.International ophthalmology · 2024Review
- Spotlight on iron and ferroptosis: research progress in diabetic retinopathy.Frontiers in endocrinology · 2023Review
- TRIM46 aggravated high glucose-induced hyper permeability and inflammatory response in human retinal capillary endothelial cells by promoting IκBα ubiquitination.Eye and vision (London, England) · 2022Article
- Metformin, A Potential Role in Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.Ophthalmology and therapy · 2021Review
- Pathological changes in the cellular structures of retina and choroidea in the early stages of alloxan-induced diabetes.World journal of diabetes · 2018Article
- Associations between erythropoietin polymorphisms and risk of diabetic microvascular complications.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a common endocrine disorder associated with peripheral microvascular diseases such as proliferative retinal microangiopathy (or diabetic retinopathy), which may lead to blindness. Unfortunately, diabetic microvascular abnormalities in the choroid are underestimated in clinical practice. Recent literature has revealed that the severity of diabetic retinopathy is aggravated by choroidopathy resulting from hyperglycemia. Here, we introduce a case of diabetic retinopathy with choroidal neovascularization membrane but without signs of retinal microvascular proliferation or drusen. We investigated the pathogenesis of choroidal microvascular proliferation secondary to diabetes. We postulate that choroidal neovascularization is an intraocular microvascular complication of diabetes mellitus. Intravitreal anti-vascular endothelial growth factor therapy may be a treatment option for microvascular proliferation in both retina and choroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.